Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I

BACKGROUND: In the COMFORT-I study, the Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib provided significant reductions in splenomegaly, improvements in myelofibrosis (MF)-related symptoms, and a survival advantage relative to placebo in patients with intermediate-2 or high-risk MF. This post-hoc ana...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Lymphoma Myeloma Leuk
Autori principali: Mesa, Ruben A., Verstovsek, Srdan, Gupta, Vikas, Mascarenhas, John, Atallah, Ehab, Burn, Timothy, Sun, William, Sandor, Victor, Gotlib, Jason
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4418454/
https://ncbi.nlm.nih.gov/pubmed/25682576
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2014.12.008
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi